479 Tim-3 ALTERS IL12/IL23 BALANCE AND DRIVES TH17 CELLS; ROLE IN HEPATITIS B VACCINE FAILURE DURING HEPATITIS C INFECTION

jonathan p moorman,jia m wang,cheng j ma,x wu,penny thayer,pamela greer,a mcintyre,kevin p high,zhi q yao

DOI: https://doi.org/10.1016/s0168-8278(13)60481-x

IF: 25.7

2013-01-01

Journal of Hepatology

Abstract:POSTERS samples were applied.The aim was to re-analyze sequential plasma and PBMC samples from patients who resolved CHC and became HCV RNA negative by clinical laboratory testing.Methods: Plasma samples (n = 60) from 11 randomly selected patients who resolved CHC after a standard course of PEG/IFN/RBV therapy were collected before (n = 12), during (range 48-68 wks; n = 28) and up to 33.1 (range 12-88) wks post-treatment (n = 20).PBMCs (n = 26) from 4 patients before (n = 5), during (n = 13) and post-treatment (n = 8) were also analyzed.Total RNA was extracted from 250 or 750 ml plasma and intact or PHA-stimulated PBMCs.HCV RNA was detected by RT-PCR/nucleic acid hybridization (RT-PCR/NAH; sensitivity <5 copies/mg RNA or <2 IU/ml).Clone sequence analysis of the HCV 5 -UTR from sequential plasma and PBMCs was done in 2 patients.Results: HCV RNA was detected in 9 of 20 (45.3%) plasma and 4 of 8 (50%) PBMC samples for up to 23.6 wks (range 12-59 wks) after completion of treatment.Among plasma samples identified during therapy as negative for HCV RNA by clinical assay, 64.3% were reactive by RT-PCR/NAH.Testing of RNA from 750 ml plasma increased HCV detection from 31.7% to 63.3% (38/60) compared to 250-ml samples.Testing naïve versus PHA-stimulated PBMCs enhanced HCV detection from 26.9% to 69.2% (18/26).Virus replicative strand was detected in 12/18 PBMC samples.Mutations identified in the 5 -UTR sequence persisted in plasma and/or PBMCs during and after PEG-IFN/RBV therapy.The frequency of HCV detection tended to decline in both plasma and PBMCs with longer follow-up.Conclusions: HCV can persist at levels not detectable by standard clinical assays in both plasma and PBMC after clinically apparent resolution of CHC due to PEG-IFN/RBV therapy.The findings suggest the need for continued evaluation even after patients achieve undetectable HCV RNA post-treatment.